Announcements
- Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
- Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
- Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
- Applied Therapeutics Announces $100 Million Private Placement
- Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
- Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
- Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
- Applied Therapeutics Reports Third Quarter 2023 Financial Results
More ▼
Key statistics
On Thursday, Applied Therapeutics Inc (2UV:FRA) closed at 4.46, -38.65% below its 52-week high of 7.27, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.45 |
---|---|
High | 4.46 |
Low | 4.45 |
Bid | -- |
Offer | -- |
Previous close | 4.76 |
Average volume | 1.06k |
---|---|
Shares outstanding | 105.89m |
Free float | 98.58m |
P/E (TTM) | -- |
Market cap | 511.43m USD |
EPS (TTM) | -1.42 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 14:29 BST.
More ▼